These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 16022066)

  • 1. Assessment of health state utilities for attention-deficit/hyperactivity disorder in children using parent proxy report.
    Matza LS; Secnik K; Rentz AM; Mannix S; Sallee FR; Gilbert D; Revicki DA
    Qual Life Res; 2005 Apr; 14(3):735-47. PubMed ID: 16022066
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Health state utilities for childhood attention-deficit/hyperactivity disorder based on parent preferences in the United kingdom.
    Secnik K; Matza LS; Cottrell S; Edgell E; Tilden D; Mannix S
    Med Decis Making; 2005; 25(1):56-70. PubMed ID: 15673582
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Health-related quality of life in children and adolescents who have a diagnosis of attention-deficit/hyperactivity disorder.
    Klassen AF; Miller A; Fine S
    Pediatrics; 2004 Nov; 114(5):e541-7. PubMed ID: 15520087
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Do parents and children agree on rating a child's HRQOL? A systematic review and Meta-analysis of comparisons between children with attention deficit hyperactivity disorder and children with typical development using the PedsQL
    Lee YC; Yang HJ; Lee WT; Teng MJ
    Disabil Rehabil; 2019 Feb; 41(3):265-275. PubMed ID: 29057670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: a double-blind, placebo-controlled trial.
    Kelsey DK; Sumner CR; Casat CD; Coury DL; Quintana H; Saylor KE; Sutton VK; Gonzales J; Malcolm SK; Schuh KJ; Allen AJ
    Pediatrics; 2004 Jul; 114(1):e1-8. PubMed ID: 15231966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Psychometric validation of the child health questionnaire (CHQ) in a sample of children and adolescents with attention-deficit/hyperactivity disorder.
    Rentz AM; Matza LS; Secnik K; Swensen A; Revicki DA
    Qual Life Res; 2005 Apr; 14(3):719-34. PubMed ID: 16022065
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between quality of life and treatment response in children with attention Deficit Hyperactivity Disorder and their parents.
    van der Kolk A; Bouwmans CA; Schawo SJ; Buitelaar JK; van Agthoven M; Hakkaart-van Roijen L
    J Ment Health Policy Econ; 2014 Sep; 17(3):119-29. PubMed ID: 25543115
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preference-based measurement of health-related quality of life (HRQL) in children with chronic musculoskeletal disorders (MSKDs).
    Brunner HI; Maker D; Grundland B; Young NL; Blanchette V; Stain AM; Feldman BM
    Med Decis Making; 2003; 23(4):314-22. PubMed ID: 12926581
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Responsiveness of the Adult Attention-Deficit/Hyperactivity Disorder Quality of Life Scale (AAQoL).
    Matza LS; Johnston JA; Faries DE; Malley KG; Brod M
    Qual Life Res; 2007 Nov; 16(9):1511-20. PubMed ID: 17874207
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Parent-proxy EQ-5D ratings of children with attention-deficit hyperactivity disorder in the US and the UK.
    Matza LS; Secnik K; Mannix S; Sallee FR
    Pharmacoeconomics; 2005; 23(8):777-90. PubMed ID: 16097840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of patients' and parents' quality of life in a randomized placebo-controlled atomoxetine study in attention-deficit/hyperactivity disorder.
    Escobar R; Montoya A; Polavieja P; Cardo E; Artigas J; Hervas A; Fuentes J
    J Child Adolesc Psychopharmacol; 2009 Jun; 19(3):253-63. PubMed ID: 19519260
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A modeled economic evaluation comparing atomoxetine with stimulant therapy in the treatment of children with attention-deficit/hyperactivity disorder in the United Kingdom.
    Cottrell S; Tilden D; Robinson P; Bae J; Arellano J; Edgell E; Aristides M; Boye KS
    Value Health; 2008; 11(3):376-88. PubMed ID: 18489664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relationships Between Functional Outcomes and Symptomatic Improvement in Atomoxetine-Treated Adult Patients with Attention-Deficit/Hyperactivity Disorder: Post Hoc Analysis of an Integrated Database.
    De Bruyckere K; Bushe C; Bartel C; Berggren L; Kan CC; Dittmann RW
    CNS Drugs; 2016 Jun; 30(6):541-58. PubMed ID: 27224994
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improvement in health-related quality of life in children with ADHD: an analysis of placebo controlled studies of atomoxetine.
    Perwien AR; Faries DE; Kratochvil CJ; Sumner CR; Kelsey DK; Allen AJ
    J Dev Behav Pediatr; 2004 Aug; 25(4):264-71. PubMed ID: 15308927
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the value of atomoxetine in treating children and adolescents with ADHD in the UK.
    Prasad S; Arellano J; Steer C; Libretto SE
    Int J Clin Pract; 2009 Jul; 63(7):1031-40. PubMed ID: 19570121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effectiveness of atomoxetine and quality of life in children with attention-deficit/hyperactivity disorder as perceived by patients, parents, and physicians in an open-label study.
    Wehmeier PM; Dittmann RW; Schacht A; Minarzyk A; Lehmann M; Sevecke K; Lehmkuhl G
    J Child Adolesc Psychopharmacol; 2007 Dec; 17(6):813-30. PubMed ID: 18315453
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atomoxetine treatment in children and adolescents with attention-deficit hyperactivity disorder: what are the long-term health-related quality-of-life outcomes?
    Perwien AR; Kratochvil CJ; Faries DE; Vaughan BS; Spencer T; Brown RT
    J Child Adolesc Psychopharmacol; 2006 Dec; 16(6):713-24. PubMed ID: 17201615
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Atomoxetine response in the inattentive and combined subtypes of attention deficit hyperactivity disorder: a retrospective chart review.
    Ercan ES; Akyol Ardic U; Kabukcu Basay B; Ercan E; Basay O
    Atten Defic Hyperact Disord; 2013 Dec; 5(4):377-85. PubMed ID: 23737214
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Results from 2 proof-of-concept, placebo-controlled studies of atomoxetine in children with attention-deficit/hyperactivity disorder.
    Spencer T; Heiligenstein JH; Biederman J; Faries DE; Kratochvil CJ; Conners CK; Potter WZ
    J Clin Psychiatry; 2002 Dec; 63(12):1140-7. PubMed ID: 12523874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Findings from the observational COMPLY study in children and adolescents with ADHD: core symptoms, ADHD-related difficulties, and patients' emotional expression during psychostimulant or nonstimulant ADHD treatment.
    Dittmann RW; Banaschewski T; Schacht A; Wehmeier PM
    Atten Defic Hyperact Disord; 2014 Dec; 6(4):291-302. PubMed ID: 24705867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.